Buy or sell Metacrine stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

View More Companies

Metacrine Stock

Metacrine is a privately held biotech company

Founded

2015

Notable Investors

ARCH Venture Partners

Headquarters

San Diego CA, US

Total Funding

$123M

About Metacrine Stock

Metacrine is a privately held biotech company  founded in 2015 on technology licensed from the  laboratory of Dr. Ronald Evans, a world leader in  nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.

Investors

ARCH Venture Partners

Codiak Biosciences, Metacrine, Beam Therapeutics, Mindstrong Health

Franklin Templeton Investments

LegalZoom, Sweetgreen, Sumo Logic, Rent the Runway, ClearMotion, Optoro, Metacrine, IEX Group

Funding History

August 2015	$36.0M
December 2017	$22.0M
June 2018	$65.0M

Management

CEO

Neil McDonnell

CFO

Trisha Millican

CEO & President

Ken Song

Press

Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist

GlobeNewswire (press release) - Jun, 13 2018

Metacrine Completes $65M Series C Financing

FinSMEs (blog) - Jun, 8 2018

Metacrine to Present at 30th Annual ROTH Conference and HC Wainwright & Co. 2nd Annual NASH Investor Conference

PR Newswire (press release) - Mar, 7 2018

Metacrine raises $22M to advance liver drug for humans

The San Diego Union-Tribune - Dec, 7 2017

Other Companies

Learn More

Evolve Biosystems

Evolve BioSystems is developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome.

$69.0MTotal Funding

Learn More

HealthLeap

Search and Review Site for Patients seeking Doctors

$0Total Funding

Learn More

MindMaze

MindMaze operates a platform to build intuitive human machine interfaces combining VR, computer graphics, brain imaging, and neuroscience.

$109MTotal Funding

Learn More

Verb Surgical

Verb Surgical is a digital surgery platform that combines robotics, advanced visualization, advanced instrumentation, data analytics.

$0Total Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Metacrine or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 80K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2020 EquityZen Inc. All rights reserved.